{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-025241","form_type":"8-K/A","ticker":"VNDA","cik":"0001347178","company_name":"Vanda Pharmaceuticals Inc.","filed_at":"2024-05-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.036432+00:00","generated_at":"2026-06-01T08:38:38.739473+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Vanda board rejects conditional resignation of director Chrousos after less-than-majority vote","bullets":["Director Phaedra S. Chrousos received less than majority votes at 2024 annual meeting, tendered conditional resignation.","Board (excluding Chrousos) unanimously voted May 22, 2024 to reject resignation, citing qualifications and proxy advisory firm's recommendation related to Rights Agreement.","Chrousos will continue as director until Vanda's 2027 annual meeting or until successor elected."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-025241","json":"https://secwatch.observer/filing/0001628280-24-025241.json","markdown":"https://secwatch.observer/filing/0001628280-24-025241.md","text":"https://secwatch.observer/filing/0001628280-24-025241.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347178/000162828024025241/0001628280-24-025241-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347178/000162828024025241/vnda-20240517.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T08:38:38.739473+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}